Most Read Articles
06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 06 Jul 2020
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 5 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Plecanatide favourable for older individuals with CIC, IBS-C

Audrey Abella
16 Jun 2020

The guanylate cyclase-C receptor agonist plecanatide is effective and well-tolerated by older individuals (≥65 years) with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), results of a post hoc analysis presented at DDW 2020 has shown.

CIC and IBS-C are common chronic gastrointestinal disorders that represent a spectrum of diseases known as functional bowel disorders. [Gastroenterology 2016;150:1393-1407] Although evidence has shown the efficacy of prosecretory agents for short-term treatment of both conditions, data on their efficacy and safety among the elderly are limited. [Pharmacotherapy 2015;35:613-630]

The team pooled data from four 12-week, phase III trials (two CIC and two IBS-C; n=4,973) that randomized participants 1:1:1 to receive plecanatide 3 or 6 mg, or placebo. Of these, 468 were elderly (mean age 70 years, 30 percent male). [DDW 2020, abstract Sa1712]

At week 12, stool consistency in the elderly cohort was significantly improved with both plecanatide doses vs placebo (least-squares [LS] mean, 1.49 vs 0.92; p=0.002 [3 mg] and LS mean, 1.48 vs 0.92; p=0.004 [6 mg]).

Weekly stool frequency was significantly greater with plecanatide 3 mg vs placebo, be it for complete spontaneous bowel movements (CSBM; LS mean, 2.63 vs 1.56; p=0.003) or spontaneous bowel movements (SBM; LS mean, 3.27 vs 1.90; p=0.003).

Moreover, the times from start of treatment to first CSBM were significantly shorter with both plecanatide doses vs placebo (p<0.05 for both).Time to first SBM was substantially shorter with the 6-mg plecanatide dose vs placebo (p<0.05); borderline significance was observed between plecanatide 3 mg and placebo (p=0.05).

Diarrhoea was the most commonly reported treatment-emergent adverse event (TEAE; ranging from 4–5 percent). However, the rates of discontinuation due to diarrhoea were low (1.7–2 percent), and no serious cases were observed. Other common TEAEs reported were headache, flatulence, arthralgia, upper respiratory infection, and nasopharyngitis.

“This is the largest pooled analysis of patients with CIC and IBS-C in the elderly population to date. [Our] results indicate that plecanatide is well-tolerated and effective … for older adult patients with CIC or IBS-C,” said the researchers. The findings correlated with the overall study findings as well as the results pertaining to the younger cohort, they added.

CIC and IBS-C may impair quality of life and work productivity, and carry a substantial cost burden. [J Manag Care Spec Pharm 2014;20:382-390; Am J Gastroenterol 2015;110:580-587] Despite the various therapeutic options* available, no single algorithm suits all patients given the heterogeneity of both conditions. [N Engl J Med 2017;376:2566-2578] Alternatives can provide options in case of initial treatment failure or intolerance. [P T 2018;43:207-209]

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 06 Jul 2020
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 5 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.